Bizarre Patents
Ballistic resistant body covering
A ballistic resistant body covering for protecting the torso, groin and neck area from ballistic missiles.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7666439 | Mycoplasma hyopneumoniae bacterin vaccine The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin an... | 02/23/2010 |
| 7635481 | Canine vaccine for protection against ehrlichiosis The present invention provides a safe and effective vaccine composition which comprises: an effective immunizing amount of an inactivated Ehrlichia canis bacterin; a pharmacologically acceptable carrier; and an immunogenically stimulating amount of an adjuvan... | 12/22/2009 |
| 7622124 | bacterin vaccine The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin an... | 11/24/2009 |
| 7575752 | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric in... | 08/18/2009 |
| 7345152 | Monoclonal antibody specific for an epitope of inactivated feline immunodeficiency-encoded glycoprotein The present invention provides a monoclonal antibody specific for an epitope which is unique to the surface protein component of an inactivated feline immunodeficiency virus (FIV) envelope glycoprotein. Said antibody is useful for the quantification of inactivated F... | 03/18/2008 |
| 7306807 | Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting... | 12/11/2007 |
| 7279166 | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric in... | 10/09/2007 |
| 7276353 | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric in... | 10/02/2007 |
| 7169398 | Equine protozoal myeloencephalitis vaccine The present invention provides an immunogenically active component comprising inactivated Sarcocystis neurona cells and/or inactivated Neospora hughesi cells; antigens derived therefrom; DNA derived therefrom; or a mixture; or in combination with other... | 01/30/2007 |
| 7169394 | bacterin vaccine The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin an... | 01/30/2007 |
| 7018638 | Mycoplasma hyopneumoniae bacterin vaccine The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin an... | 03/28/2006 |
| 5422122 | Controlled release potassium chloride tablet A pharmaceutical dosage form is prepared from a multiplicity of coated potassium chloride crystals coated with two distinct layers, the first of ethylcellulose and the second of a hydrophilic coating polymer, preferably hydroxypropylcellulose, resulting i... | 06/06/1995 |
| 5306506 | Pharmaceutical composition for rapid suspension in water The invention provides a solid pharmaceutical composition for addition to water to produce a suspension of a drug comprising (a) a drug which is substantially water-insoluble or microencapsulated; (b) a thickening or suspending agent; (c) a pharmaceutical... | 04/26/1994 |
| 5196149 | Preparation of high solids, low viscosity carbonless paper gelatin base microcapsules This disclosure is directed to a high solid, low viscosity carbonless paper gelatin base microcapsule system producing microcapsules having sizes characteristically from about 3 to about 10 microns (micrometers) and being characterized as single oil drop ... | 03/23/1993 |
| 5095151 | Preparation of propranolol hydrochloride macrocrystals There is described a process for the preparation of high yields of propranolol hydrochloride having a particle size within the range of 420 to 1200 microns wherein the propanolol hydrochloride is recrystallized from, as a solvent, a mixture of n-propanol ... | 03/10/1992 |
| 5047238 | Adjuvants for vaccines An efficacious parenterally administered inactivated canine coronavirus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent canine coronavirus is produced. A method for propaga... | 09/10/1991 |
| 5013663 | Canine corona virus vaccine An efficacious parenterally administered modified live Canine Corona virus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent Canine Corona virus is produced. A method for pro... | 05/07/1991 |
| 4933184 | Menthol enhancement of transdermal drug delivery Disclosed herein are compositions and methods for enhancing the transdermal delivery of physiologically active agents across mammalian skin or membranes and which comprise a percutaneous transfer enhancing amount of menthol and a drug.... | 06/12/1990 |
| 4931283 | Menthol enhancement of transdermal drug delivery Disclosed herein are compositions and methods for enhancing the transdermal delivery of physiologically active agents across mammalian skin or membranes and which comprise a percutaneous transfer enhancing amount of menthol and a drug.... | 06/05/1990 |
| 4888360 | Carvone enhancement of transdermal drug delivery Disclosed herein are compositions and methods for enhancing the transdermal delivery of physiologically active agents across mammalian skin or membranes and which comprise a percutaneous transfer enhancing amount of 1-carvone and a drug.... | 12/19/1989 |
| 4888362 | Eugenol enhancement of transdermal drug delivery Disclosed herein are compositions and methods for enhancing the transdermal delivery of physiologically active agents across mammalian skin or membranes and which comprise a percutaneous transfer enhancing amount of eugenol and a drug.... | 12/19/1989 |
| 4874695 | Rapid indentification of yeast and other fungal microorganisms by enzyme detection Rapid identification of different species of microorganism selected from fungi and yeast like algae is accomplished by culturing the microorganism for several hours under normal conditions on a non-inhibitory mycological medium which stimulates the microo... | 10/17/1989 |
| 4873266 | Menthone enhancement of transdermal drug delivery Disclosed herein are compositions and methods for enhancing the transdermal delivery of physiologically active agents across mammalian skin or membranes and which comprise a percutaneous transfer enhancing amount of 1-menthone and a drug.... | 10/10/1989 |
| 4824785 | Canine corona virus vaccine An efficacious parenterally administered modified live Canine Corona virus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent Canine Corona virus is produced. A method for pro... | 04/25/1989 |
| 4761378 | Microbiological testing apparatus An improved microbiological test tray is described which are provided with fasteners so that two or more of the trays may be joined together for ease in inoculation, incubation, lyophilization and reading. In another aspect of the invention an improved tr... | 08/02/1988 |
| 4649049 | Rabies vaccine A rabies vaccine composition is disclosed which comprises a sterilized suspension of proteineous suckling mice or rat brain particles of injectable particle size laden with an amount of inactivated rabies virus which is equivalent to a virus titer of at l... | 03/10/1987 |
| 4600575 | Aerosol anesthetic compositions Novel liquid anesthetic aerosol composition comprising high concentrations of benzocaine in a water washable base with propellants which are resistant to cold temperatures are disclosed.... | 07/15/1986 |
| 4567043 | Canine corona virus vaccine An efficacious parenterally administered modified live Canine Corona virus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent Canine Corona virus is produced. A method for pro... | 01/28/1986 |
| 4567042 | Inactivated canine coronavirus vaccine An efficacious parenterally administered inactivated canine coronavirus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent canine coronavirus is produced. A method for propaga... | 01/28/1986 |
| 4554248 | Composition and method for detecting Antistreptolysin O A composition is used as a reagent in a method for measuring Antistreptolysin O (ASO) in a blood sample. The composition contains Streptolysin O (SO) at a pH outside the range of its hemolytic activity, e.g., outside the pH range of 5-9. At that pH the SO... | 11/19/1985 |
| 4442118 | Aldose reductase inhibition by 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid Disclosed are new methods of using 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid, or a therapeutically acceptable salt thereof with an organic or inorganic base for the treatment of complications associated with diabetes mellitus. The ... | 04/10/1984 |
| 4423060 | Aldose reductase inhibition by 1-methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid Disclosed are new methods of using 1-methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid or a therapeutically acceptable salt thereof with an organic or inorganic base for the treatment of complications associated with diabetes mellitus. The compound ... | 12/27/1983 |
| 4423075 | Aldose reductase inhibition by 5-fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-1H-indene-3-ac etic acid Disclosed are new methods of using 5-fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-1H-indene-3-acet ic acid or a therapeutically acceptable salt thereof with an organic or inorganic base for the treatment of complications associated with diabetes... | 12/27/1983 |
| 4423074 | Aldose reductase inhibition by 5-fluoro-2-methyl-1-[[4-(methylthio)phenyl]me]-1H-indene-3-acetic acid Disclosed are new methods of using 5-fluoro-2-methyl-1-[[4-(methylthio)phenyl]methylene]-1H-indene-3-acetic acid or a therapeutically acceptable salt thereof with an organic or inorganic base for the treatment of complications associated with diabetes ... | 12/27/1983 |
| 4405625 | Method of treating hyperglycemia with 1,3-dioxo-1H-benz[de]isoquinoline-2(3H)-acetic acid A method is disclosed for lowering blood glucose levels in a diabetic mammal by administering an effective amount of 1,3-dioxo-1H-benz[de]isoquinoline-2(3H)-acetic acid.... | 09/20/1983 |
| 4361582 | Aldose reductase inhibition by γ-oxo-8-fluoranthenebutanoic acid Disclosed are new methods of using γ-oxo-8-fluoranthenebutanoic acid, or a therapeutically acceptable salt thereof with an organic or inorganic base for the treatment of complications associated with diabetes mellitus. The compound inhibits lens aldose r... | 11/30/1982 |
| 4351158 | Method of producing multicomponent lyophilized product At least two incompatible solutions are simultaneously charged into a container maintained at a temperature substantially below the freezing temperature of each solution in such predetermined amounts that the separate charges of solution freeze on the wal... | 09/28/1982 |
| 4346090 | 13-Chloro-benzocycloheptapyridoisoquinolines and use as neuroleptics 13-Chloro-octahydrobanzo[6,7]cyclohepta[1,2,3-de]pyrido[2,1-a]isoquinolin-5 -ols, substituted on the piperidine ring with lower alkyl or a cycloalkyl are disclosed. The compounds are useful CNS depressants. Methods for their preparation and use also are di... | 08/24/1982 |
| 4344934 | Therapeutic compositions with enhanced bioavailability Novel compositions comprising wetted mixtures of poorly soluble drugs with water soluble polymers useful in increasing bioavailability are disclosed.... | 08/17/1982 |
| 4321260 | Method of using gonadorelin for the treatment of benign prostatic hyperplasia Herein is described a method of treating benign prostatic hyperlasia without affecting testicular weight in a male mammal by administering an effective amount of gonadorelin.... | 03/23/1982 |
